COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Also, Scripps does not provide COVID-19 tests for asymptomatic patients. See FAQs.

An Option for Stroke Protection for AFib Patients Undergoing Ablation

Trial ID:
Douglas Gibson, M.D.
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation

Inclusion Criteria

Patients must:
  • Be 18 years of age or older
  • Have undergone a prior catheter ablation procedure for non-valvular atrial fibrillation within 90 days of consent
  • Be willing and able to return for required follow-up visits and examinations

Exclusion Criteria

Patients must not:
  • Be enrolled in another investigational study
  • Have had a stroke or transient ischemic attack (TIA) within the past 60 days of consent
  • Have an active infection
  • Have had surgical closure of the left atrial appendage

Additional Info

  • All treatments and physician visits during the study will take place at Anderson Medical Pavilion.
  • For more information search NCT# 03795298 on the Clinical Trials website at

Contact Info:

  • Clinical Research Leadership